Cargando…
L‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study
BACKGROUND: The survival of children with acute lymphoblastic leukemia (ALL) has improved due to changes in the treatment and the disease diagnosis. A significant advance was the incorporation of asparaginase. However, hypersensitivity reactions are a common cause of early discontinuation of this dr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351670/ https://www.ncbi.nlm.nih.gov/pubmed/34431241 http://dx.doi.org/10.1002/cnr2.1533 |
_version_ | 1784762484459044864 |
---|---|
author | dos Santos, Amanda Cabral dos Santos, Julia Maria Bispo da Costa Lima, Elisangela Land, Marcelo Gerardin Poirot |
author_facet | dos Santos, Amanda Cabral dos Santos, Julia Maria Bispo da Costa Lima, Elisangela Land, Marcelo Gerardin Poirot |
author_sort | dos Santos, Amanda Cabral |
collection | PubMed |
description | BACKGROUND: The survival of children with acute lymphoblastic leukemia (ALL) has improved due to changes in the treatment and the disease diagnosis. A significant advance was the incorporation of asparaginase. However, hypersensitivity reactions are a common cause of early discontinuation of this drug. AIM: The proposed study aims to evaluate early interruptions and the influence of the number of asparaginase doses effectively administered on the prognosis of patients with ALL. METHODS AND RESULTS: An observational cohort study was carried out, with retrospective data collection, in medical records. The prognostic variables indicated in the protocol applied were used, and the principal outcomes were 5 years event‐free survival (EFS) and 5 years of overall survival (OS) probability. Statistical analyzes were performed using SPPS 20.0 and R. In Cox's proportional hazards model for EFS and OS, variables of prognostic importance (n = 126 children) were: high‐risk group (HGR), by the protocol classification, and less than 10 doses of asparaginase. The increased risk of events and death in HGR, who did less than 10 doses, was 3.6 and 7 times, respectively. The study did not show statistical significance for the number of asparaginase doses in patients who were not at high risk. CONCLUSIONS: We demonstrated that the early interruption of asparaginase treatment could negatively impact the prognosis of patients with ALL, especially HGR, reinforcing the need for careful diagnosis of reactions and the availability of alternative types of asparaginase. |
format | Online Article Text |
id | pubmed-9351670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93516702022-08-09 L‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study dos Santos, Amanda Cabral dos Santos, Julia Maria Bispo da Costa Lima, Elisangela Land, Marcelo Gerardin Poirot Cancer Rep (Hoboken) Original Articles BACKGROUND: The survival of children with acute lymphoblastic leukemia (ALL) has improved due to changes in the treatment and the disease diagnosis. A significant advance was the incorporation of asparaginase. However, hypersensitivity reactions are a common cause of early discontinuation of this drug. AIM: The proposed study aims to evaluate early interruptions and the influence of the number of asparaginase doses effectively administered on the prognosis of patients with ALL. METHODS AND RESULTS: An observational cohort study was carried out, with retrospective data collection, in medical records. The prognostic variables indicated in the protocol applied were used, and the principal outcomes were 5 years event‐free survival (EFS) and 5 years of overall survival (OS) probability. Statistical analyzes were performed using SPPS 20.0 and R. In Cox's proportional hazards model for EFS and OS, variables of prognostic importance (n = 126 children) were: high‐risk group (HGR), by the protocol classification, and less than 10 doses of asparaginase. The increased risk of events and death in HGR, who did less than 10 doses, was 3.6 and 7 times, respectively. The study did not show statistical significance for the number of asparaginase doses in patients who were not at high risk. CONCLUSIONS: We demonstrated that the early interruption of asparaginase treatment could negatively impact the prognosis of patients with ALL, especially HGR, reinforcing the need for careful diagnosis of reactions and the availability of alternative types of asparaginase. John Wiley and Sons Inc. 2021-08-24 /pmc/articles/PMC9351670/ /pubmed/34431241 http://dx.doi.org/10.1002/cnr2.1533 Text en © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles dos Santos, Amanda Cabral dos Santos, Julia Maria Bispo da Costa Lima, Elisangela Land, Marcelo Gerardin Poirot L‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study |
title | L‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study |
title_full | L‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study |
title_fullStr | L‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study |
title_full_unstemmed | L‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study |
title_short | L‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study |
title_sort | l‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: a survival analysis study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351670/ https://www.ncbi.nlm.nih.gov/pubmed/34431241 http://dx.doi.org/10.1002/cnr2.1533 |
work_keys_str_mv | AT dossantosamandacabral lasparaginasedosesnumberasaprognosticfactorinchildhoodacutelymphoblasticleukemiaasurvivalanalysisstudy AT dossantosjuliamariabispo lasparaginasedosesnumberasaprognosticfactorinchildhoodacutelymphoblasticleukemiaasurvivalanalysisstudy AT dacostalimaelisangela lasparaginasedosesnumberasaprognosticfactorinchildhoodacutelymphoblasticleukemiaasurvivalanalysisstudy AT landmarcelogerardinpoirot lasparaginasedosesnumberasaprognosticfactorinchildhoodacutelymphoblasticleukemiaasurvivalanalysisstudy |